Therapeutic Approaches to Drug Targets in Leukemia
Mahesh Vitthal Rathod and Seema Vitthal Rathod
Journal Title:International Journal of Ayurveda and Pharmaceutical Chemistry
Non-communicable diseases like cancer are responsible for major social and health burden as millions of people are dying every year. Out of which, Leukemia is the leading cause of deaths worldwide. The ionizing radiation, chemotherapeutic agent and certain chemicals exposure are the risk factor for leukemia. Both genetic and environmental components are associated with the development of leukemia cells. Immune and inflammatory mediators have a complex role in the initiation and progression of leukemia. Understanding of all these processes will help to invent a range of new biomarkers and novel treatment modalities targeting various cellular events in acute and chronic inflammation that are accountable for leukemia. Several biochemical pathways, receptors and enzymes are involved in the development of leukemia that would be possible targets for improving strategies for disease diagnosis and management. However, the novel drug target like tyrosine kinase inhibitors, mcl-1inhibitor, jak-stat inhibitor, mTOR inhibitors, and mitogen-activated protein kinase (MEK) inhibitors, Heat shock protein inhibitors are more powerful to control the process of leukemia. Therefore, the review briefly focuses on different novel targets that act at starting stage in the formation of leukemia.